Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.
A cyclin-dependent kinase inhibitor CDKN2A (p16/Ink4a) is a tumor suppressor and upregulated in cellular senescence. CDKN2A promoter methylation and gene silencing are associated with the CpG island methylator phenotype (CIMP) in colon cancer. However, prognostic significance of CDKN2A methylation or loss of CDKN2A (p16) expression independent of CIMP status remains uncertain. Using a database of 902 colorectal cancers in 2 independent cohort studies (the Nurses' Health Study and the Health Professionals Follow-up Study), we quantified CDKN2A promoter methylation and detected hypermethylation in 269 tumors (30%). By immunohistochemistry, we detected loss of CDKN2A (p16) expression in 25% (200/804) of tumors. We analyzed for LINE-1 hypomethylation and hypermethylation at 7 CIMP-specific CpG islands (CACNA1G, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1); microsatellite instability (MSI); KRAS, BRAF and PIK3CA mutations; and expression of TP53 (p53), CTNNB1 (β-catenin), CDKN1A (p21), CDKN1B (p27), CCND1 (cyclin D1), FASN (fatty acid synthase) and PTGS2 (cyclooxygenase-2). CDKN2A promoter methylation and loss of CDKN2A (p16) were associated with shorter overall survival in univariate Cox regression analysis [hazard ratio (HR): 1.36, 95% CI: 1.10-1.66, p = 0.0036 for CDKN2A methylation; HR: 1.30, 95% CI: 1.03-1.63, p = 0.026 for CDKN2A (p16) loss] but not in multivariate analysis that adjusted for clinical and tumor variables, including CIMP, MSI and LINE-1 methylation. Neither CDKN2A promoter methylation nor loss of CDKN2A (p16) was associated with colorectal cancer-specific mortality in uni- or multivariate analysis. Despite its well-established role in carcinogenesis, CDKN2A (p16) promoter methylation or loss of expression in colorectal cancer is not independently associated with patient prognosis.
Shima
Kaori
K
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA. shuji_ogino@dfci.harvard.edu
Nosho
Katsuhiko
K
Baba
Yoshifumi
Y
Cantor
Mami
M
Meyerhardt
Jeffrey A
JA
Giovannucci
Edward L
EL
Fuchs
Charles S
CS
Ogino
Shuji
S
D000368:Aged; D015179:Colorectal Neoplasms / Q000235:genetics*; D019175:DNA Methylation; D005260:Female; D019942:Genes, p16; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011401:Promoter Regions, Genetic; D011446:Prospective Studies
Int J Cancer. 2010 Aug 15;127(4):873-80
20013803
Gastroenterology. 2009 Jan;136(1):196-205.e2
18951899
N Engl J Med. 2007 May 24;356(21):2131-42
17522398
Histopathology. 2008 Nov;53(5):588-98
18983468
J Mol Diagn. 2008 Jan;10(1):13-27
18165277
Cell. 2007 Jul 27;130(2):223-33
17662938
Curr Opin Immunol. 2009 Aug;21(4):431-9
19535234
PLoS One. 2008;3(11):e3698
19002263
Hum Pathol. 2007 Jun;38(6):842-9
17350669
J Cancer Res Clin Oncol. 2010 Feb;136(2):323-31
19779933
Cancer Res. 2001 Apr 15;61(8):3225-9
11309270
Clin Cancer Res. 2007 Oct 15;13(20):6093-8
17947473
Int J Cancer. 2008 Jul 1;123(1):14-21
18425817
Mod Pathol. 2006 Jan;19(1):59-68
16118624
Cancer Res. 2009 Sep 15;69(18):7422-9
19723657
J Clin Oncol. 2005 Jan 20;23(3):609-18
15659508
J Mol Diagn. 2006 May;8(2):209-17
16645207
J Clin Oncol. 2001 Jan 15;19(2):299-304
11208819
Gut. 2009 Jan;58(1):90-6
18832519
Int J Oncol. 2004 Feb;24(2):349-55
14719111
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6
10411935
Cancer Lett. 2008 Sep 18;268(2):177-86
18471961
Ann Surg Oncol. 2010 Jul;17(7):1767-76
20077021
Int J Cancer. 2009 Jul 1;125(1):84-90
19326430
Gastroenterology. 2005 Sep;129(3):837-45
16143123
Int J Cancer. 2008 Feb 15;122(4):796-801
17957798
Neoplasia. 2008 Jun;10(6):534-41
18516290
J Surg Oncol. 2003 Nov;84(3):143-50
14598358
Int J Cancer. 2008 Jun 15;122(12):2767-73
18366060
Int J Cancer. 2008 May 15;122(10):2255-9
18224685
J Mol Diagn. 2007 Jul;9(3):305-14
17591929
Clin Cancer Res. 2006 Feb 15;12(4):1184-91
16489072
Oncol Rep. 2003 Jul-Aug;10(4):935-8
12792748
J Pathol. 2006 Oct;210(2):147-54
16850502
Clin Cancer Res. 2003 Aug 1;9(8):2898-903
12912934
Cancer Biol Ther. 2005 Dec;4(12):1389-94
16322687
Mol Med. 2008 Jul-Aug;14(7-8):412-21
18418463
Hum Pathol. 2004 Oct;35(10):1189-95
15492985
Int J Cancer. 2010 Jul 15;127(2):367-80
19908233
J Mol Diagn. 2006 Nov;8(5):582-8
17065427
J Clin Oncol. 2010 Jan 20;28(3):466-74
20008640
Clin Cancer Res. 2009 May 1;15(9):3156-62
19383812
Virchows Arch. 2009 Dec;455(6):485-94
19911194
J Mol Diagn. 2005 Aug;7(3):413-21
16049314
J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9
16872319
Pathology. 2008 Oct;40(6):580-5
18752124
Cancer Res. 2008 Oct 15;68(20):8541-6
18922929
J Clin Oncol. 2003 Oct 15;21(20):3729-36
14551292
J Mol Diagn. 2010 Mar;12(2):177-83
20093385
Oncology. 1999;57(2):149-56
10461063
World J Gastroenterol. 2007 Feb 28;13(8):1187-94
17451198
Hum Pathol. 2007 Apr;38(4):585-92
17239930
Neoplasia. 2006 Jun;8(6):429-36
16820088
World J Gastroenterol. 2003 Oct;9(10):2202-6
14562378
Clin Cancer Res. 2008 May 1;14(9):2560-9
18451217
J Clin Oncol. 2005 Apr 1;23(10):2318-24
15800322
J Natl Cancer Inst. 2008 Dec 3;100(23):1734-8
19033568
Neoplasia. 2007 Jul;9(7):569-77
17710160
Nat Genet. 2006 Jul;38(7):787-93
16804544
Dig Dis. 2005;23(2):151-5
16352895
Neoplasia. 2006 Jun;8(6):458-64
16820091